cytarabine has been researched along with plx4032 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baidildina, D; Bronin, G; Burtsev, E; Cherniak, E; Dzhukaeva, I; Erega, E; Evseev, D; Fink, O; Ignatova, A; Kalinina, I; Kotskaya, N; Litvin, E; Lyudovskikh, E; Maschan, A; Maschan, M; Novichkova, G; Osipova, D; Popov, A; Pristanskova, E; Purbueva, B; Raykina, E; Semchenkova, A; Vlasova, I; Voronin, K; Zhogov, V | 1 |
1 other study(ies) available for cytarabine and plx4032
| Article | Year |
|---|---|
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
Topics: Child; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Neoplasm Recurrence, Local; Proto-Oncogene Proteins B-raf; Vemurafenib | 2023 |